Soligenix (NASDAQ:SNGX) has been given a $5.00 target price by equities researchers at Maxim Group in a note issued to investors on Wednesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s target price indicates a potential upside of 108.33% from the stock’s previous close.

Separately, HC Wainwright reissued a “buy” rating and set a $5.50 price objective (down previously from $11.00) on shares of Soligenix in a research report on Monday, November 6th.

Soligenix (NASDAQ SNGX) traded up $0.16 during midday trading on Wednesday, hitting $2.40. The company had a trading volume of 114,841 shares, compared to its average volume of 332,450. Soligenix has a fifty-two week low of $1.74 and a fifty-two week high of $5.08. The firm has a market cap of $19.56, a PE ratio of -2.38 and a beta of 2.17.

Soligenix (NASDAQ:SNGX) last posted its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.15. Soligenix had a negative return on equity of 112.81% and a negative net margin of 90.93%. The business had revenue of $1.82 million during the quarter, compared to analysts’ expectations of $1.36 million. equities analysts anticipate that Soligenix will post -1.28 EPS for the current year.

In other news, insider Spa Essetifin purchased 293,510 shares of the stock in a transaction that occurred on Wednesday, November 29th. The shares were purchased at an average cost of $2.12 per share, for a total transaction of $622,241.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 5.03% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Daily Political and is the property of of Daily Political. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at

Soligenix Company Profile

Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with's FREE daily email newsletter.